CD163 and breast carcinoma: Based on our knowledge, this is the first study that demonstrated the expression of CD163 in cancer cells and its correlation with poor prognosis in OSCC, which is consistent with the studies in breast cancer, colorectal cancer and malignant melanoma [6, 9, 28, 29].